GLP-1 Market Global Assessment Report 2026 to 2035

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimer's Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2034"

The Global GLP-1 Market is valued at USD 50.0 Billion in 2024, and it is expected to reach USD 141.9 Billion by the year 2034, with a CAGR of 11.1% during the forecast period of 2025-2034..

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592

Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone secreted by the gastrointestinal tract, playing a critical role in the regulation of glucose homeostasis and appetite. GLP-1 receptor agonists are pharmacological agents designed to activate GLP-1 receptors, producing multiple clinically significant effects, including the stimulation of glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release, delayed gastric emptying, and enhanced peripheral glucose uptake. These mechanisms collectively facilitate effective glycemic control in patients with type 2 diabetes while supporting weight reduction, providing a therapeutic advantage for individuals with obesity and related metabolic disorders.

The GLP-1 receptor agonist market comprises both approved and investigational therapies, encompassing short-acting agents such as exenatide and lixisenatide, alongside long-acting formulations including semaglutide, dulaglutide, and liraglutide. The introduction of oral therapies, exemplified by oral semaglutide (Rybelsus), has enhanced patient convenience and accessibility, further supporting market adoption.

Next-generation GLP-1 agents, including dual- and tri-agonists such as tirzepatide that target multiple hormonal pathways, represent a significant advancement in the management of metabolic diseases. Market growth is primarily driven by the rising global prevalence of type 2 diabetes and obesity, alongside the established efficacy, safety, and therapeutic versatility of current GLP-1 therapies. Ongoing innovation, active clinical development, and expanding therapeutic indications are expected to sustain the market's growth trajectory in the foreseeable future.

List of Prominent Players in the GLP-1 Market:
• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The global GLP-1 receptor agonist market is being propelled by the rising prevalence of type 2 diabetes and obesity. Epidemiological studies indicate that diabetes prevalence increased from 3.0% to 4.1%, while obesity rates rose from 32.7% to 40.9% between 2009 and 2020, according to the Journal of the American Medical Association. GLP-1 receptor agonists have demonstrated substantial clinical efficacy, including significant reductions in blood glucose levels, lowered HbA1c, and meaningful weight loss.

Regulatory approvals, such as semaglutide (Wegovy) for obesity management in addition to diabetes treatment, have expanded the eligible patient population, thereby accelerating market adoption. Improved insurance coverage, affordability, and advancements in drug delivery-including oral formulations and once-weekly injectable options-have enhanced patient convenience, adherence, and long-term therapeutic outcomes.

Challenges:
Despite their clinical benefits, several factors constrain the broader adoption of GLP-1 receptor agonists. Gastrointestinal side effects, such as nausea and vomiting, can limit patient tolerance and adherence. While once-weekly injectable formulations improve convenience, the need for subcutaneous administration remains a barrier for some patients. Oral therapies, including oral semaglutide, have improved accessibility; however, demand persists for ultra-long-acting agents that reduce dosing frequency. Additionally, the high cost of therapy and disparities in insurance coverage, particularly in low- and middle-income countries, restrict widespread market penetration.

Regional Trends:
The Asia-Pacific (APAC) region is emerging as a high-growth market for GLP-1 receptor agonists, driven by increasing incidences of diabetes and obesity in countries such as China, India, and Japan. Market expansion is supported by enhanced healthcare infrastructure, greater focus on chronic disease management, and a substantial underserved patient population. Growing demand for effective therapies for metabolic disorders is encouraging leading pharmaceutical companies to strengthen their regional presence and invest in the development and commercialization of advanced GLP-1 receptor agonists, positioning APAC as a key growth frontier within the global market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2592

Recent Developments:
• In November 2023, The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
• In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes. The funds will also be used to advance several first-in-class programs and establish a clinical trial manufacturing facility.

Segmentation of GLP-1 Market-
By Type of Molecule:
• Biologics
• Small Molecules
By Active Compound Used:
• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds
By Type of GLP-1 Agonist Drugs:
• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist
By Type of Agonist:
• Single agonist
• Dual agonist
• Tri-agonist
By Route of Administration:
• Oral
• Parenteral
By Target Indication:
• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/glp-1-market/2592

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.